"The Mechanic" Cellular Energy Optimization Protocol

Your cells run on a system with a very specific sequence, and understanding that sequence is the only way to understand why any individual intervention works or doesn't work.

Here is the whole chain first.

Your mitochondria produce ATP through a process called the electron transport chain, which is a series of protein complexes embedded in the inner mitochondrial membrane that pass electrons down a gradient, and that gradient drives the spinning of a molecular motor that stamps out ATP. The membrane has to be intact for that gradient to hold. The electrons have to be carried between those complexes. And the cells doing all of this work have to actually be functional, not sitting there in a state called senescence, which is when a cell stops dividing, refuses to die, and starts consuming resources while contributing nothing and actively signaling damage to everything around it.

Those are the three failure points as you age. Membrane integrity, electron transport efficiency, and the senescent cell burden that pulls NAD+ away from the whole system.

Start with the membrane.

The inner mitochondrial membrane is folded into structures called cristae, and the structural integrity of those folds depends on a phospholipid called cardiolipin, which acts like the scaffolding that keeps the electron transport chain complexes positioned correctly relative to each other. When cardiolipin gets damaged through normal oxidative stress and aging, the cristae lose their architecture, the complexes drift apart, electrons start leaking out before they complete the chain, and instead of producing ATP that leaked electron reacts with oxygen to produce something called reactive oxygen species, which is a category of unstable molecules that damage everything nearby including more cardiolipin. It is a self-accelerating problem.

A compound called SS-31 was developed specifically to bind cardiolipin on the inner mitochondrial membrane and stabilize it. Research published in the Journal of the American Society of Nephrology showed that SS-31 selectively concentrates in the inner mitochondrial membrane, binds cardiolipin directly, and in doing so restores cristae architecture, reduces electron leakage, and cuts ROS production. The dose range used clinically starts conservatively at 1 to 2 milligrams per day, and the intervention is run for four to eight weeks because membrane remodeling takes time and you are not trying to flood the system, you are trying to interrupt the damage cycle long enough for the membrane to stabilize.

During this same period, you can run a parallel intervention targeting senescent cells, because the senescent cell problem is not just a structural problem, it is a resource problem.

Senescent cells accumulate with age and they produce something called the SASP, which stands for senescence-associated secretory phenotype, and it is essentially a constant inflammatory signal that recruits macrophages to the area. Those macrophages upregulate an enzyme called CD38, and CD38 degrades NAD+. Research published in Nature Metabolism established this causal chain directly: senescent cell signals cause macrophage CD38 to rise, and that CD38 activity is responsible for a significant portion of the NAD+ decline you see with aging. Separately, data from Cell Metabolism showed that CD38 activity increases two to three fold with age, and that mice without CD38 maintained their NAD+ levels across their entire lifespan.

So the senescent cells are not just inflamed tissue, they are actively draining the fuel supply that your repaired mitochondria need to operate.

FOXO4-DRI clears them by exploiting how senescent cells stay alive. Normal cells, when they are damaged enough, undergo apoptosis, which is programmed self-destruction. Senescent cells block that process by locking a protein called FOXO4 into a complex with p53, which prevents p53 from triggering apoptosis even when the cell is clearly dysfunctional. FOXO4-DRI is a peptide that competes with endogenous FOXO4 for that binding site, disrupts the complex, and frees p53 to do its job. Research published in Cell in 2017 found 11.73-fold selectivity for senescent cells versus healthy cells, meaning the mechanism preferentially acts on the cells you want to remove and largely leaves the healthy ones alone.

The clearance of those cells is not comfortable. When the immune system processes large numbers of dying senescent cells in a short window, you will feel it, and that is normal and expected.

The third piece of the repair phase is Epithalon, which works through a different mechanism entirely. Epithalon is a tetrapeptide that induces expression of hTERT, which is the catalytic subunit of telomerase, and telomerase is the enzyme that maintains telomere length at the ends of chromosomes. Research in human fibroblasts confirmed that Epithalon exposure induced telomerase activity and resulted in measurable telomere elongation. The standard course is 500 micrograms to one milligram per day for 10 to 20 days, run one to two times per year.

Once the repair phase is complete, the optimization phase begins, and the logic shifts.

MOTS-c is a peptide derived from the mitochondrial genome itself, which makes it categorically different from exogenous compounds. It activates something called AMPK, which is a sensor inside cells that detects the ratio of AMP to ATP and responds when energy is low by upregulating mitochondrial biogenesis and improving metabolic efficiency. Research from Cell Metabolism showed that MOTS-c activates AMPK through inhibition of the folate cycle, and that this activation prevented diet-induced obesity and insulin resistance in animal models. The practical effect is that MOTS-c pushes the repaired mitochondria to operate at higher efficiency, which is why the sequence matters. Running MOTS-c before repair is like flooring the accelerator in an engine that is leaking oil.

NAD+ support fits here as well, and the mechanism matters for understanding why niacin is the rational choice.

NMN and NR have been marketed as direct NAD+ precursors, and the pathway they use is real. But research published in Science Advances in 2025 confirmed that most oral NMN and NR is converted to niacin-pathway metabolites in the gut before it is absorbed anyway, meaning you are largely paying a significant premium for something that arrives at the same place niacin does, at a fraction of the cost. If you are already injecting NAD+ directly, you are bypassing that conversion entirely, and that is a legitimate route. But for oral supplementation, niacin accomplishes the same endpoint.

L-carnitine fits as an optional addition because long-chain fatty acids cannot cross the inner mitochondrial membrane on their own. They require a shuttle, and carnitine is that shuttle. Without adequate carnitine, fatty acids queue up outside the mitochondria and cannot enter beta-oxidation. Injectable L-carnitine at 200 to 500 milligrams bypasses any absorption variability in the gut and delivers the cofactor directly.

CoQ10 sits underneath all of this as a non-negotiable foundation because CoQ is the mobile carrier that physically moves electrons between Complex I and Complex III in the electron transport chain. Without it, the chain stalls regardless of how well the membrane is maintained or how much NAD+ is available. CoQ10 levels decline measurably with age, and statin medications accelerate that decline by blocking the same synthetic pathway that produces cholesterol.

The thing worth sitting with is that the order of operations in this protocol is not arbitrary. The membrane has to be stable before you push output. The senescent cells have to be cleared before NAD+ will stay elevated. The optimization signal has to arrive at mitochondria that are actually capable of responding to it. Most people approaching this space reach for the output-boosting compounds first because those are the ones that have the most marketing behind them, and then they are confused when the effect is smaller than expected. The infrastructure determines what the intervention can do.

---

References

1. Birk AV, Liu S, Soong Y, et al. The Mitochondrial-Targeted Compound SS-31 Re-Energizes Ischemic Mitochondria by Interacting with Cardiolipin. Journal of the American Society of Nephrology. 2013;248:1250-1261. Finding: SS-31 selectively binds cardiolipin on the inner mitochondrial membrane, stabilizing cristae structure. Source
2. Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. British Journal of Pharmacology. 2014;1718:2029-2050. Finding: SS-31 binds cardiolipin, stabilizes mitochondrial membrane structure, and reduces electron leakage and ROS production. Source
3. Baar MP, Brandt RMC, Putavet DA, et al. Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. Cell. 2017;1691:132-147. Finding: FOXO4-DRI disrupts FOXO4-p53 interaction in senescent cells, freeing p53 to trigger apoptosis. 11.73-fold selectivity for senescent vs healthy cells. Source
4. Camacho-Pereira J, Tarrago MG, Chini CCS, et al. CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism. Cell Metabolism. 2016;236:1127-1139. Finding: CD38 activity increases 2-3 fold with age. CD38 knockout mice maintained NAD+ levels at all ages. Source
5. Covarrubias AJ, Kale A, Perrone R, et al. Senescent cells promote tissue NAD+ decline during ageing via the activation of CD38+ macrophages. Nature Metabolism. 2020;211:1265-1283. Finding: Senescent cell SASP cytokines induce macrophages to upregulate CD38, establishing the causal chain from senescence to NAD+ decline. Source
6. Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of Experimental Biology and Medicine. 2003;1356:590-592. Finding: Epithalon induced hTERT expression, telomerase activity, and telomere elongation in human fibroblasts. Source
7. Goncharova ND, Vengerin AA, Khavinson VKh, Lapin BA. Pineal peptides restore the age-related disturbances in hormonal functions of the pineal gland and the pancreas. Experimental Gerontology. 2005;401-2:51-57. Finding: Epithalamin at 5mg/day and synthetic Epithalon at 10mcg/day achieved equivalent melatonin restoration in aged monkeys, demonstrating 500-fold potency difference. Source
8. Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;213:443-454. Finding: MOTS-c activates AMPK via inhibition of the folate cycle. Prevented insulin resistance and diet-induced obesity. Source
9. Shats I, Williams JG, Liu J, et al. Bacteria Boost Mammalian Host NAD Metabolism by Engaging the Deamidated Biosynthesis Pathway. Cell Metabolism. 2020;313:564-579. Finding: Gut bacteria deamidate nicotinamide to nicotinic acid niacin, confirming NMN/NR undergo gut conversion before absorption. Source
10. Kim LJ, et al. Nicotinamide riboside and nicotinamide mononucleotide facilitate NAD+ synthesis via enterohepatic circulation. Science Advances. 2025. Finding: Most oral NMN and NR is converted to niacin-pathway metabolites in the gut before absorption. Source
11. Costford SR, Bajpeyi S, Pasarica M, et al. Skeletal muscle NAMPT is induced by exercise in humans. American Journal of Physiology - Endocrinology and Metabolism. 2010;2981:E117-E126. Finding: NAMPT protein increased 127% in sedentary subjects after exercise training. Source
12. Longo N, Frigeni M, Pasquali M. Carnitine transport and fatty acid oxidation. Biochimica et Biophysica Acta. 2016;186310:2422-2435. Finding: L-carnitine is the sole molecule carrying long-chain fatty acids across the inner mitochondrial membrane for beta-oxidation. Source
13. Banerjee R, Purhonen J, Bhardwaj R, Bhargava A, Kallijarvi J. The mitochondrial coenzyme Q junction and complex III. The FEBS Journal. 2022;28922:6936-6958. Finding: CoQ serves as the mobile electron carrier between Complex I/II and Complex III. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness